BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...

KUALA LUMPUR, April 28 (Bernama) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, has announced the first clinical use of its LithiX Hertz Contact (HC) ...

MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz ...

MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiXTM ...

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium ...

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...

Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs focal stress contact points to ...

MILPITAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Elixir Medical , a developer of disruptive technologies to treat cardiovascular disease, today announced EU MDR CE Mark approval and commercial ...